Publication:
Potential drug–drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors

Simple item page
dc.contributor.authorFernández de Palencia Espinosa, María Ángeles
dc.contributor.authorDíaz Carrasco, María Sacramento
dc.contributor.authorAlonso Romero, José Luis
dc.contributor.authorRubia Nieto, Amelia de la
dc.contributor.authorEspuny Miró, Alberto
dc.contributor.departmentMedicina
dc.date.accessioned2024-11-07T12:42:45Z
dc.date.available2024-11-07T12:42:45Z
dc.date.issued2015-09-21
dc.description© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015. This document is the Published version of a Published Work that appeared in final form in International Journal of Clinical Pharmacy. To access the final edited and published work see https://doi.org/10.1007/s11096-015-0195-z
dc.description.abstractBackground Oncological patients are at high risk for drug–drug interactions (DDIs), which may contribute to therapeutic failure or lead to serious adverse events. Objective To determine the prevalence of potential DDIs in medication lists, to describe the most frequent DDIs and to investigate the possible risk factors associated with them. A prospective cohort study was performed at the Oncology Department of a tertiary hospital over a 12-week period. Twice a week, every inpatient’s treatment sheet was collected and screened through two databases: Micromedex™ and Drug Interaction Facts™. All identified potential DDIs with a moderate or higher severity rating were recorded. Multivariate analysis was used to identify risk factors associated with DDIs. Result A total of 1956 DDIs were detected in 699 treatment sheets. The prevalence of treatment sheets with DDIs was 81.0 % and 32.6 % by Micromedex™ and Drug Interaction Facts™, respectively. Central nervous depressant agents and antiemetics were the most commonly involved groups in DDIs. A higher number of non-antineoplastic drugs was related with potential DDIs [adjusted-OR 1.398 and 1.613 by Micromedex™ and Drug Interaction Facts™, respectively]. Conclusion The prevalence of potential DDIs was widely variable among databases. The main risk factor associated with DDIs was a higher number of non-antineoplastic medicines.es
dc.formatapplication/pdfes
dc.format.extent7es
dc.identifier.citationInt J Clin Pharm (2015) 37:1021–1027
dc.identifier.doihttps://doi.org/10.1007/s11096-015-0195-z
dc.identifier.issnPrint: 2210-7703
dc.identifier.issnElectronic: 2210-7711
dc.identifier.urihttp://hdl.handle.net/10201/146090
dc.languageenges
dc.publisherSpringer
dc.relationSin financiación externa a la Universidades
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s11096-015-0195-z
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAdultes
dc.subjectAntineoplastic agentes
dc.subjectDrug-drug interactiones
dc.subjectInpatientes
dc.subjectSpaines
dc.titlePotential drug–drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factorses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
s11096-015-0195-z.pdf
Size:
344.62 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos